Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Holding DXCM?
Track your performance easily
DXCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$62.34 - $142.00
Previous CloseN/A
Volume488.69K
Average Volume (3M)3.43M
Market Cap
$30.92B
Enterprise Value$27.60B
Total Cash (Recent Filing)$123.70M
Total Debt (Recent Filing)$6.70M
Price to Earnings (P/E)48.2
Beta0.85
Next Earnings
Feb 13, 2025EPS Estimate
0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding390,595,400
10 Day Avg. Volume3,831,252
30 Day Avg. Volume3,426,414
Standard Deviation0.14
R-Squared0.18
Alpha0.00286
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.94
Price to Cash Flow (P/CF)39.40
P/FCF Ratio86.20
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue6.98
Enterprise Value/Gross Profit12.06
Enterprise Value/Ebitda28.36
Forecast
1Y Price Target
$96.78Price Target Upside14.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Dexcom News
Bulls Say, Bears Say
Bulls Say
Market ExpansionDexCom's continuous glucose monitoring system currently enjoys a leading share of the ~$10B worldwide CGM market.
Product DevelopmentG8 progress is encouraging, with the potential to offer multi-analyte capabilities and a multi-year set-up for future catalysts and sentiment boosts.
Revenue GrowthDexCom preannounced Q4 revenue of at least $1,113M, beating both the analyst's estimate and consensus.
Bears Say
Gross Margin ImpactQ4 gross margin is approximately 60%, which is below the estimated 63.5% due to inventory damage and production yield issues.
Market PerformanceThe stock suffered in after-hours trading from the year-over-year decline in US revenue, which also missed estimates, making it tougher to ease investor fears of a slowing market.
Revenue DeclineDXCM's 2% U.S. revenue decline was several points worse than expected, with price and mix headwinds reaching an all-time high, indicating it could take several quarters before U.S. growth returns to double-digits.
---
Ownership Overview
0.41% Insiders
28.79% Mutual Funds
0.35% Other Institutional Investors
40.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $62.34 and its highest was $142.00 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $30.92B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Feb 13, 2025 which is in 26 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 24, 2024. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.435 by $0.015.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.51.
How many shares outstanding does Dexcom have?
Dexcom has 390,595,400 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.45 in its last earnings report, beating expectations of $0.435. Following the earnings report the stock price went down -1.884%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 692M.
---
Dexcom Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.78 (14.07% Upside)
$96.78 (14.07% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 79%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.83%
12-Months-Change
Fundamentals
Return on Equity
32.06%
Trailing 12-Months
Asset Growth
-3.67%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
DXCM Company Deck
---
DXCM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced outlook with significant achievements such as record new customer starts and international growth offset by challenges in the U.S. market, particularly in revenue and DME channel dynamics. The launch of Stelo and a strategic focus on the 15-day sensor submission demonstrate proactive steps towards future growth.Read More>---
DXCM Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$96.78
▲(14.07% Upside)
Technical Analysis
Insulet
―
Tandem Diabetes Care
―
Edwards Lifesciences
―
Medtronic
―
Zimmer Biomet Holdings
―
Boston Scientific
―
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
34/46 ratings generated profit
1 Year Average Return
+38.71%
assigned a buy rating 3 months ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 73.91% of your transactions generating a profit, with an average return of +38.71% per trade.
---